ATE313802T1 - Bestimmung von adrenomedullin-bindenden proteinen - Google Patents

Bestimmung von adrenomedullin-bindenden proteinen

Info

Publication number
ATE313802T1
ATE313802T1 AT00961705T AT00961705T ATE313802T1 AT E313802 T1 ATE313802 T1 AT E313802T1 AT 00961705 T AT00961705 T AT 00961705T AT 00961705 T AT00961705 T AT 00961705T AT E313802 T1 ATE313802 T1 AT E313802T1
Authority
AT
Austria
Prior art keywords
methods
complexes
factor
binding proteins
provides
Prior art date
Application number
AT00961705T
Other languages
English (en)
Inventor
Frank Cuttitta
Ted H Elsasser
Alfredo Martinez
Ruben Pio
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE313802T1 publication Critical patent/ATE313802T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00961705T 1999-09-10 2000-09-08 Bestimmung von adrenomedullin-bindenden proteinen ATE313802T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15339799P 1999-09-10 1999-09-10
PCT/US2000/024722 WO2001018550A2 (en) 1999-09-10 2000-09-08 Determination of adrenomedullin-binding proteins

Publications (1)

Publication Number Publication Date
ATE313802T1 true ATE313802T1 (de) 2006-01-15

Family

ID=22547062

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961705T ATE313802T1 (de) 1999-09-10 2000-09-08 Bestimmung von adrenomedullin-bindenden proteinen

Country Status (9)

Country Link
US (3) US20070025915A1 (de)
EP (1) EP1214600B1 (de)
AT (1) ATE313802T1 (de)
AU (1) AU774725B2 (de)
CA (1) CA2383419A1 (de)
DE (1) DE60025008T2 (de)
ES (1) ES2254220T3 (de)
PT (1) PT1214600E (de)
WO (1) WO2001018550A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7430081B2 (en) 2002-02-28 2008-09-30 Emcore Corporation Sub-micron adjustable mount for supporting a component and method
JPWO2003078460A1 (ja) * 2002-03-19 2005-07-14 株式会社オンコレックス ペプチド、該ペプチドを含有する医薬組成物及び癌治療用医薬組成物
US7364719B2 (en) 2002-10-04 2008-04-29 The United States Of America As Represented By The Department Of Health And Human Services Vasoregulating compounds and methods of their use
EP1575511A4 (de) 2002-11-07 2006-06-28 Us Gov Health & Human Serv Neues target für die angiogenese- und anti-angiogenese-therapie
WO2004097423A1 (en) * 2003-04-25 2004-11-11 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
AU2004273057C1 (en) * 2003-09-08 2011-06-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
US8703693B2 (en) * 2004-03-31 2014-04-22 The Feinstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
EP1742651B1 (de) 2004-03-31 2011-03-09 The Feinstein Institute for Medical Research Adrenomedullin und adrenomedullin-bindungsprotein zur ischämie/reperfusionsbehandlung
EP1800131A2 (de) * 2004-09-09 2007-06-27 Bayer HealthCare AG Diagnostika und therapeutika für krankheiten in zusammenhang mit dem adrenomedullin-rezeptor (amdr)
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
JP4976412B2 (ja) * 2005-12-01 2012-07-18 ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
DE102006052916A1 (de) * 2006-11-08 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Diabetes mellitus mittels MR-proADM
US8088715B2 (en) * 2007-11-13 2012-01-03 Ikonisys, Inc. Detection of circulating tumor cells in peripheral blood with an automated scanning fluorescence microscope
ITMI20080357A1 (it) * 2008-03-04 2009-09-05 Sarm Allergeni Srl Proteina da haliotis midae e suo uso come agente immunoterapico
EP2211182A1 (de) * 2009-01-16 2010-07-28 Roche Diagnostics GmbH Verfahren zur Bewertung des Schweregrades einer Leberzirrhose
PT3553084T (pt) 2011-11-16 2023-02-17 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou esqueleto não-ig anti-adm para prevenção ou redução de disfunção de órgãos ou insuficiência de órgãos num paciente possuindo uma doença crónica ou aguda ou condição aguda
SG11201402358RA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
IL283215B2 (en) * 2011-11-16 2024-05-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same
EP2780717B1 (de) 2011-11-16 2016-12-21 sphingotec GmbH Adrenomedullintests und verfahren zur bestimmung von reifem adrenomedullin
SG11201402354YA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
US20150093331A1 (en) * 2013-10-01 2015-04-02 OncoLock Co., Ltd. Biomarkers for breast cancer
US10675306B2 (en) 2015-12-08 2020-06-09 The University Of North Carolina At Chapel Hill Adrenomedullin therapy to improve fetal implantation
EP3438668A1 (de) * 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnose und risikostratifizierung von pilzinfektionen
MX2020004072A (es) * 2017-10-18 2020-07-28 Adrenomed Ag Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm).

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US4774323A (en) * 1987-06-29 1988-09-27 Rorer Pharmaceutical Corporation Purification of von Willebrand Factor solutions using gel permeation chromatography
US5641685A (en) * 1995-04-24 1997-06-24 Smithkline Beecham Corporation Method carboxy terminal protein or peptide sequencing
WO1997007214A1 (en) * 1995-08-18 1997-02-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology

Also Published As

Publication number Publication date
US20070025915A1 (en) 2007-02-01
WO2001018550A3 (en) 2001-08-02
WO2001018550A9 (en) 2002-09-26
AU774725B2 (en) 2004-07-08
EP1214600B1 (de) 2005-12-21
US20100098703A1 (en) 2010-04-22
DE60025008T2 (de) 2006-09-14
WO2001018550A2 (en) 2001-03-15
US7659081B2 (en) 2010-02-09
CA2383419A1 (en) 2001-03-15
US7993857B2 (en) 2011-08-09
ES2254220T3 (es) 2006-06-16
EP1214600A2 (de) 2002-06-19
US20090053734A1 (en) 2009-02-26
DE60025008D1 (de) 2006-01-26
PT1214600E (pt) 2006-05-31
AU7362200A (en) 2001-04-10

Similar Documents

Publication Publication Date Title
DE60025008D1 (de) Bestimmung von adrenomedullin-bindenden proteinen
DE69715861D1 (de) Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression
DE60028970D1 (de) An her2 bindende peptidverbindungen
ATE451390T1 (de) Polypeptide zur bindung an das b-lymphozyten- stimulatorische protein (blys)
WO2001055307A8 (en) Nucleic acids, proteins, and antibodies
KR101155294B1 (ko) 면역특이적으로 BLyS에 결합하는 항체
ATE165395T1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
BG101392A (en) Method of treating diabetes mellitus using kgf
WO2003061559A3 (en) Binding peptides specific for the extracellular domain of erbb2 and uses therefor
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
MXPA02008239A (es) Gen humano de la esquizofrenia.
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
ATE192490T1 (de) Für einen humanen serotoninrezeptor (5-ht4b) kodierende dns und ihre verwendung
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE190318T1 (de) Pcna bindende substanz
WO2002026930A3 (en) Nucleic acids, proteins, and antibodies
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2001041813A3 (en) Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
ATE316136T1 (de) Nierenpolycystose-gen
DE69615185D1 (de) Faktor ix bindende peptide abgeleitet von faktor vii und ihre verwendung als inhibitoren der blutgerinnung
NO992531L (no) Fremgangsmåter ved fremstilling av rekombinant protein
DE69734890D1 (de) Rdgb-proteine
DE69712182D1 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties